摘要:
Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. Also disclosed are compositions containing a compound in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.
摘要:
The invention concerns 1,7-diarylpentamethine and 1,9-diarylhetptamethine salts, in particular heptacarbon or nonacarbon carboxonium salts, and streptocyanines. The compounds correspond to the formula [G-D-G'] Q wherein Q is a strong acid anion, and G and G' represent independently of each other a OEt, amino, hydrazono, hydrazino, phosphaimino, amidino or guanidino group, or a multivalent radical optionally bound at least at one of its other ends to another group D; D represents a cationic 1,7-diarylpentamethine or 1,9-diarylheptamethine group wherein the aryl groups bear substituents representing independently of one another a hydrogen, a halogen, an alkyl radical or an alkoxy radical having 1 to 15 carbon atoms or a acetamido CH3C(O)HN- group.
摘要:
The invention concerns a method for making hydrazine in aqueous solution, characterised in that it comprises the following steps which consist in: a) in a reaction medium, preparing 2,2,4,4-tetramethyl-3-pentanone azine by oxidising coupling of 2,2,4,4-tetramethyl-3-pentanone imine in the presence of a catalytic system and oxygen as oxidising agent; b) hydrolysing 2,2,4,4-tetramethyl-3-pentanone azine to obtain hydrazine in aqueous solution and 2,2,4,4-tetramethyl-3-pentanone in the form of an organic phase.
摘要:
Compounds of formula (I) in which X is (a) or (b), n is 0, 1, 2, 3, 4 or 5, where if n is greater than 1, the radicals R2 are identical or different; o is 0, 1, 2, 3 or 4, where if o is greater than 1, the radicals R3 are identical or different; R1 is perhalo-C1-C4alkoxy; R2 is halogen, C1-C8alkyl, halo-C1-C8alkyl, C1-C8alkoxy, halo-C1-C8alkoxy, C1-C8alkylthio, halo-C1-C8alkylthio, C1-C8alkylsulfynyl, halo-C1-C8alkylsulfynyl, C1-C8alkylsulfonyl, halo-C1-C8alkylsulfonyl, CN or phenyl; R3 is halogen, C1-C8alkyl, halo-C1-C8alkyl or halo-C1-C8alkoxy; R4 is H, halogen, C1-C8alkyl, C3-C6cycloalkyl, halo-C1-C8alkyl, C1-C8alkoxy, C1-C8alkoxy-C1-C8alkyl, C1-C8alkoxy-C1-C8alkoxy, C1-C8alkylthio or NR8R9; R5 is C1-C8alkyl, NR10R11, OR20, SR20 or SO2R20; R6 is H, C1-C8alkyl, C3-C6cycloalkyl, halo-C1-C8alkyl, C1-C8alkenyl, C1-C8alkynyl, C1-C8acyl or phenyl; R7 is H, an unsubstituted or substituted C1-C8alkyl, C3-C6cycloakyl, C3-C6cycloalkyl-C1-C8alkyl, C1-C8alkenyl, C1-C8alkynyl, C3-C6cycloalkenyl, C3-C6cycloalkenyl-C1-C8alkyl or C3-C6cycloalkyl-C1-C8alkenyl group, it being possible for the substituents to be selected from the group consisting of halogen, C1-C8alkyl, halo-C1-C8alkyl, C1-C8alkoxy, halo-C1-C8alkoxy, C1-C8alkyl-S(O)p, it being possible for p to be 0, 1 or 2, C1-C8alkoxycarbonyl, di(C1-C8alkyl)amino and C1-C8alkanoyloxy; an unsubstituted or substituted phenyl or heteroaryl group, it being possible for the substituents to be selected from the group consisting of C1-C6alkyl and halogen; C1-C8alkoxy, NR16R17, COOR6 or SR6; R8 and R9 independently of one another are H, C1-C8alkyl or OH; R10 is H, C1-C8alkyl, C3-C6cycloalkyl, halo-C1-C8alkyl, halo-C1-C8alkoxy-C1-C8alkyl, phenyl, OR12, S(O)mR13, m being 0, 1 or 2, or NR14R15; R11 is H, C1-C8alkyl, C3-C6cycloalkyl, halo-C1-C8alkyl, C1-C8alkoxy-C1-C8alkyl, allyl, C1-C8alkylallyl, haloallyl or propargyl; R12 is H, C1-C8alkyl, halo-C1-C8alkyl, C1-C8alkoxy-C1-C8alkyl, C3-C6cycloalkyl, C2-C8alkenyl, halo-C2-C8alkenyl or propargyl; R13 is H, C1-C8alkyl, halogen-C1-C8alkyl, phenyl or NR14R15; R14 and R15 independently of one another are H, C1-C8alkyl, halo-C1-C8alkyl, phenyl, C1-C8alkylamido, di(C1-C8alkyl)amido or NH2; R16 and R17 independently of one another are H, C1-C8alkyl, halo-C1-C8alkyl, C2-C8alkenyl, C1-C8alkoxy or NH2; R18 is S(O)mR19, m being 0, 1 or 2, NO2 or CN; R19 is C1-C8alkyl, halo-C1-C8alkyl, C3-C6cycloalkyl, phenyl, benzyl or NR14R15; R20 is C1-C8alkyl, halo-C1-C8alkyl or C3-C6cycloalkyl; Y is O, S, NR18 or CHC(O)R21; and R21 is H, C1-C8alkyl, halo-C1-C8alkyl, C1-C8alkoxy or phenyl, and if appropriate, E/Z isomers and tautomers thereof, in each case in free form or in salt form, can be used as agrochemical active ingredients and may be prepared in a manner known per se.